Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The incidence, predisposing factors, localization, evolution and outcome of neoplasms following kidney transplantation were studied in two groups of patients--120 and 146 patients for an observation period from 1 to 16 years. In patients with adequate renal function who received immunosuppressive treatment for more than one year (accordingly 78 and 88 patients) neoplasms developed in 4 and 10 patients with mean duration of immunosuppressive treatment 4.9 and 6.1 years respectively. The neoplasms were: 3 skin cancers, 2 lung cancers, 2 Kaposi sarcomas, 1 lymphosarcoma, 1 breast cancer, 1 prostate cancer, 1 renal cancer, 1 rectal cancer and 2 polyps of the colon. The case fatality rate was 3.6 per cent. The importance of precision of the immunosuppressive treatment for reducing the incidence of these complications is pointed out.
 ...
PMID:[Neoplasms following kidney transplantation]. 194 1

Some evidence suggests that solvent exposures to rubber industry workers may be associated with excess cancer mortality, but most studies of rubber workers lack information about specific chemical exposures. In one large rubber and tire-manufacturing plant, however, historical documents allowed a classification of jobs based on potential exposures to all solvents that were authorized for use in the plant. A case-control analysis of a 6678 member cohort compared the solvent exposure histories of a 20% age-stratified random sample of the cohort with those of cohort members who died during 1964-1973 from stomach cancer, respiratory system cancer, prostate cancer, lymphosarcoma, or lymphatic leukemia. Of these cancers, only lymphosarcoma and lymphatic leukemia showed significant positive associations with any of the potential solvent exposures. Lymphatic leukemia was especially strongly related to carbon tetrachloride (OR = 15.3, p less than .0001) and carbon disulfide (OR = 8.9, p = .0003). Lymphosarcoma showed similar, but weaker, associations with these two solvents. Benzene, a suspected carcinogen, was not significantly associated with any of the cancers.
 ...
PMID:Cancer mortality and solvent exposures in the rubber industry. 654 4

Metallothionein (MT) promoter was methylated in rat hepatoma and in mouse lymphosarcoma cells by methylation of cytosine within the CpG dinucleotide region. After demethylation of MT-I promoter in mouse lymphosarcoma cells or in the transplanted rat hepatoma with 5-azacytidine, a potent inhibitor of DNA methyltransferase, the promoter was activated in response to heavy metal treatment. MT-I promoter was also suppressed in human prostate cancer lines PC3 and DU145, probably by promoter methylation, whereas cadmium induced MT-I in the human prostate cancer line LNCaP. In the prostate cancer lines where MT-I was suppressed, glutathione-S-transferase-pi (GST-pi) was expressed. On the contrary, GST-pi gene was repressed in the cell line where MT-I was induced, which suggests an inverse relationship between MT-I induction and GST-pi expression in some prostate cancer lines. The expressions of GST-pi and gamma-glutamyl cysteine synthase were also significantly higher (5- to 12-fold) in the lymphosarcoma cells and the hepatoma relative to the parental tissues. The higher expressions of these two genes suggest a compensatory mechanism in the cells where the gene for the antioxidant MT-I/II is not induced. MT-I/II may function as a growth suppressor either alone or in concert with other factor(s), and consequently their lack of expression could facilitate the tumor growth. In addition to suppression of MT-I/II expression by promoter methylation, the lack of MT induction could also be brought about by nuclear factor I (NFI), probably by interaction with the metal transcription factor MTF-1. An inverse relationship was observed between the level of NFI and MT-I expression in some cells, which suggests a role for NFI in the relatively low constitutive levels of MT-I expression in these cells.
 ...
PMID:Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 1242 40